Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$14.08 - $27.63 $303,240 - $595,067
-21,537 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$26.55 - $40.57 $59,047 - $90,227
-2,224 Reduced 9.36%
21,537 $572,000
Q3 2021

Nov 15, 2021

SELL
$39.27 - $72.94 $303,125 - $563,023
-7,719 Reduced 24.52%
23,761 $976,000
Q2 2021

Aug 17, 2021

BUY
$31.29 - $56.64 $704,494 - $1.28 Million
22,515 Added 251.14%
31,480 $1.78 Million
Q1 2021

May 18, 2021

SELL
$39.71 - $90.58 $4.81 Million - $11 Million
-121,035 Reduced 93.1%
8,965 $377,000
Q4 2020

Feb 12, 2021

BUY
$27.07 - $84.35 $2.84 Million - $8.86 Million
105,000 Added 420.0%
130,000 $9.11 Million
Q3 2020

Nov 13, 2020

BUY
$28.06 - $37.16 $701,500 - $928,999
25,000 New
25,000 $702,000
Q2 2019

Jul 19, 2019

SELL
$20.48 - $27.76 $1.3 Million - $1.77 Million
-63,637 Closed
0 $0
Q4 2018

Mar 08, 2019

BUY
$18.19 - $31.79 $113,341 - $198,083
6,231 Added 10.85%
63,637 $1.32 Million
Q3 2018

Oct 19, 2018

BUY
$27.65 - $38.39 $280,315 - $389,197
10,138 Added 21.45%
57,406 $1.86 Million
Q2 2018

Jul 25, 2018

BUY
$31.4 - $41.01 $193,738 - $253,031
6,170 Added 15.01%
47,268 $1.7 Million
Q1 2018

Apr 11, 2018

BUY
$29.84 - $44.08 $1.23 Million - $1.81 Million
41,098 New
41,098 $1.36 Million

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $208M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Capital Impact Advisors, LLC Portfolio

Follow Capital Impact Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Impact Advisors, LLC with notifications on news.